Efficacy and safety of PD-1 inhibitors plus chemotherapy for advanced unresectable gastroesophageal cancer: a systematic review and meta-analysis of phase III randomized controlled trials
The FDA approval of immune checkpoint inhibitors for advanced gastroesophageal cancer (GEC) independent of programmed death-ligand 1 (PD-L1) expression status has sparked notable clinical controversy, highlighting the urgent need for evidence-based evaluation of the efficacy and safety of various PD-1 inhibitors co...